Several studies using HCC cell lines suggests that ferroptosis may serve as the principal mechanism underlying the anticancer effect of sorafenib via suppressing the cystine/glutamate antiporter SLC7A11 [94–96]. Here, SLC7A11 is linked to hepatocellular carcinoma.